Protection from concanavalin A (Con A)-induced T cell-dependent hepatic lesions and modulation of cytokine release in mice by sodium fusidate

Clinical and Experimental Immunology

Volumn 110, Issue 3, 1997, Pages 479-484

  Nicoletti, F ^a,e   Beltrami, B ^b   Raschi, E ^b   Di Marco, R ^c   Magro, G ^c   Grasso, S ^d   Bendtzen, K ^b   Fiorelli, G ^b   Meroni, P L ^b  

^a UNIVERSITY OF MILAN   (Italy)

^b IRCCS   (Italy)

^c UNIVERSITY OF CATANIA   (Italy)

^d Rigshospitalet   (Denmark)

^e NONE   (Italy)

Author keywords

Autoimmune diseases; Fusidic acid; Hepatitis; Immunotherapy; T cells

Indexed keywords

CONCANAVALIN A; FUSIDATE SODIUM;

AMINOTRANSFERASE BLOOD LEVEL; ANIMAL EXPERIMENT; ARTICLE; AUTOIMMUNE HEPATITIS; CELL INFILTRATION; CONTROLLED STUDY; IMMUNOMODULATION; IMMUNOTHERAPY; MOUSE; NONHUMAN; PRIORITY JOURNAL; T LYMPHOCYTE;

EID: 0030732804     PISSN: 00099104     EISSN: None     Source Type: Journal    
DOI: 10.1046/j.1365-2249.1997.4091423.x     Document Type: Article

References (27)

1. Tiegs G, Hentschel J, Wendel A. A T cell-dependent experimental liver injury in mice inducible by concanavalin A. J Clin Invest 1992; 90:196-203.
2. Gantner F, Leist M, Lose AW, German PC, Tiegs G. Concanavalin A-induced T-cell-mediated hepatic injury in mice: the role of tumor necrosis factor. Hepatology 1995; 21:190-8.
3. Mizuhara H, O'Neill E, Seki N et al. T cell activation-associated hepatic injury: mediation by tumor necrosis factor and protection by interleukin 6. J Exp Med 1994; 179:1529-37.
4. Lohse AW, Meyer zum Bushenfelde K-H. Experimental hepatitis. In: Cohen IR, Miller A, eds. Autoimmune disease models. A guidebook. San Diego: Academic Press, 1994:191-9.
5. Decker K, Keppler D. Galactosamine hepatitis: key role of the nucleotide deficiency period in the pathogenesis of cell injury and cell death. Rev Physiol Biochem Pharmacol 1974; 71:77.
6. Howel CD, Yoder TD. Murine experimental autoimmune hepatitis: nonspecific inflammation due to adjuvant oil. Clin Immunol Immunopathol 1994; 72:76-82.
7. Nicoletti F, Meroni PL, Bendtzen K. Fusidic acid and insulin-dependent diabetes mellitus. Autoimmunity 1996; 24:187-97.
8. Ikeda K, Hirano M, Orita A, Takeuchi M. Chlorpromazine inhibits concanavalin A-induced liver injury independently of cytokine modulation. Immunol Letters 97; 55:127-31.
9. Bendtzen K, Diamant M, Faber V. Fusidic acid, an immunosuppressive drug with functions similar to cyclosporin A. Cytokine 1990; 2:423-9.
10. Nicoletti F, Zaccone P, Di Marco R et al. Effects of sodium fusidate in animal models of insulin-dependent diabetes mellitus and septic shock. Immunology 1995; 8::645-50.
11. Chen Y-L, Le Vraux V, Giroud J-P, Chauvelot-Moachon L. Anti-tumor necrosis factor properties of non-peptide drugs in acute-phase responses. Eur J Pharmacol 1994; 271:319-27.
12. Genovese F, Mancuso G, Cuzzola M, Cusumano V, Nicoletti F, Bendtzen K, Teti G. Improved survival and antagonistic effect of sodium fusidate on tumor necrosis factor alpha in a neonatal mouse model of endotoxin shock. Antimier Agents Chemother 1996; 40:1733-5.
13. Mihara M, Ikuta M, Koishihara Y, Ohsugi Y. Interleukin-6 inhibits delayed-type hypersensitivity and the development of adjuvant arthritis. Eur J Immunol 1991; 21:2327-31.
14. Schindler R, Mancilla J, Endrez S, Ghorbani R, Clark SC, Dinarello CA. Correlations and interactions in the production of interleukin-6 (IL-6), IL-1, and tumor necrosis factor (TNF) in human blood mononuclear cells: IL-6 suppresses IL-1 and TNF. Blood 1990; 75:40-47.
15. Tig H, Trehu E, Alkins MB, Dinarello CA, Mier JW. Interleukin-6 (IL-6) as an anti-inflammatory cytokine: induction of circulating IL-1 receptor antagonist and soluble tumor necrosis factor receptor p55. Blood 1994; 83:113-8.
16. Nicolelti F, Di Marco R, Morrone S et al. Reduction of spontaneous autoimmune diabetes in diabetes-prone BB rats with the novel immunosuppressant fusidic acid. Effect on T-cell proliferation and production of interferon-γ. Immunology 1994; 81:317-21.
17. Nicolelti F, Meroni PL, Lunetta M et al. Sodium fusidate and increased remission rate of insulin-dependent diabetes mellitus. Lancet 1991; 337:1292.
18. Bendlzen K, Viesti-Nielsen N, Petersen J, Andersen V, Bendixen G. Treatment of chronic endogenous uveitis with fusidic acid. Lancet 1991; 337:552-3.
19. Langholz E, Brynskov J, Freund LG, Bendtzen K. Fusidic acid for Bechet's colitis: a novel approach to T-cell specific immunosuppressive therapy. Dan Med Bull 1991; 38:28.
20. Langholz E, Brynskov J, Bendtzen K, Villen M, Binder V. Treatment of Chron's disease with fusidic acid: an antibiotic with immunosuppressive properties similar to cyclosporin. Aliment Pharmacol Ther 1992; 6:495-502.
21. Thompson AW. The spectrum of action of new immunosuppressive drugs. Clin Exp Immunol 1992; 89:170-4.
22. Toyonaga T, Hino O, Sugai S, Wakasugi S, Abe K, Shichiri M, Yamamura K-I. Chronic active hepatitis in transgenic mice expressing interferon-γ in the liver. Proc Natl Acad Sci USA 1994; 91:614-8.
23. Beasley RP, Hwang LY, Lin CC, Chien CS. Hepatocellular carcinoma and hepatitis B virus. A prospective study of 22,707 men in Taiwan. Lancet 1981; 2:1129-33.
24. Saito I, Miyamura T, Ohbayashi A et al. Hepatitis C virus infection is associated with the development of hepatocellular carcinoma. Proc Natl Acad Sci USA 1990; 87:6547-9.
25. Mondelli M, Vergani GM, Alberti A, Vergani D, Portmann B, Eddleston ALWF, Williams R, Specificity of T lymphocyte cytotoxicity to autologous hepatocytes in chronic hepatitis B virus infection: evidence that T cells are directed against HBV core antigen expressed on hepatocytes. J Immunol 1982; 129:2773-8.
26. Chisari FV, Ferrari C, Mondelli MU. Hepatitis B virus structure and biology. Microh Pathol 1989; 6:311-32.
27. Findon G, Miller TE, Rowe LC. Pharmacokinetics of fusidic acid in laboratory animals. Lab Anim Sci 1991; 41:462-5.